JP2004527510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527510A5 JP2004527510A5 JP2002573019A JP2002573019A JP2004527510A5 JP 2004527510 A5 JP2004527510 A5 JP 2004527510A5 JP 2002573019 A JP2002573019 A JP 2002573019A JP 2002573019 A JP2002573019 A JP 2002573019A JP 2004527510 A5 JP2004527510 A5 JP 2004527510A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- terminated
- substituents selected
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000002393 azetidinyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- -1 as used herein Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 125000002015 acyclic group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000021663 Female sexual arousal disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000024309 orgasm disease Diseases 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0106561A GB0106561D0 (en) | 2001-03-16 | 2001-03-16 | Pharmaceutically active compounds |
| GB0106651A GB0106651D0 (en) | 2001-03-16 | 2001-03-16 | Pharmaceutically active compounds |
| PCT/IB2002/000679 WO2002074312A1 (en) | 2001-03-16 | 2002-03-07 | Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527510A JP2004527510A (ja) | 2004-09-09 |
| JP2004527510A5 true JP2004527510A5 (enExample) | 2005-08-25 |
Family
ID=26245840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573019A Pending JP2004527510A (ja) | 2001-03-16 | 2002-03-07 | ＣＧＭＰＰＤＥ阻害剤としてのピラゾロ［４，３−ｄ］ピリミジノン化合物 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1372656B1 (enExample) |
| JP (1) | JP2004527510A (enExample) |
| AT (1) | ATE298238T1 (enExample) |
| BR (1) | BR0208078A (enExample) |
| CA (1) | CA2436911A1 (enExample) |
| DE (1) | DE60204760T2 (enExample) |
| ES (1) | ES2241994T3 (enExample) |
| MX (1) | MXPA03006310A (enExample) |
| WO (1) | WO2002074312A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
| JP2006520777A (ja) * | 2003-03-17 | 2006-09-14 | ファイザー・プロダクツ・インク | Ｐｄｅ５阻害剤を用いる１型糖尿病の治療 |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| WO2005028480A2 (en) * | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| JP5084725B2 (ja) | 2005-06-06 | 2012-11-28 | 武田薬品工業株式会社 | 有機化合物 |
| US8008332B2 (en) * | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
| WO2007143705A2 (en) | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規使用 |
| JP5701608B2 (ja) | 2007-12-06 | 2015-04-15 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| MX2011005933A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| BRPI0922131A2 (pt) | 2008-12-06 | 2015-08-18 | Intracellular Therapies Inc | Compostos orgânicos |
| BRPI0922809A2 (pt) | 2008-12-06 | 2018-05-29 | Intracellular Therapies Inc | compostos orgânicos |
| EP2367430B1 (en) * | 2008-12-06 | 2014-08-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EA201170773A1 (ru) | 2008-12-06 | 2012-01-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| BRPI0922808A2 (pt) | 2008-12-06 | 2018-05-29 | Intracellular Therapies Inc | compostos orgânicos |
| EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
| JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2956141A4 (en) | 2013-02-17 | 2016-10-26 | Intra Cellular Therapies Inc | NEW USES |
| EP2968338B1 (en) | 2013-03-15 | 2019-01-09 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries |
| PL2970279T3 (pl) | 2013-03-15 | 2021-05-31 | Intra-Cellular Therapies, Inc. | Związki organiczne |
| DK3157926T3 (da) | 2014-06-20 | 2019-08-19 | Intra Cellular Therapies Inc | Organiske forbindelser |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| US10131671B2 (en) | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
| RU2711442C2 (ru) | 2014-09-17 | 2020-01-17 | Интра-Селлулар Терапиз, Инк. | Соединения и способы |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3509589B1 (en) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Novel uses |
| US11839614B2 (en) | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
| JP7612672B2 (ja) | 2019-09-03 | 2025-01-14 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規化合物 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
-
2002
- 2002-03-07 WO PCT/IB2002/000679 patent/WO2002074312A1/en not_active Ceased
- 2002-03-07 EP EP02707031A patent/EP1372656B1/en not_active Expired - Lifetime
- 2002-03-07 BR BR0208078-8A patent/BR0208078A/pt not_active IP Right Cessation
- 2002-03-07 AT AT02707031T patent/ATE298238T1/de not_active IP Right Cessation
- 2002-03-07 JP JP2002573019A patent/JP2004527510A/ja active Pending
- 2002-03-07 DE DE60204760T patent/DE60204760T2/de not_active Expired - Fee Related
- 2002-03-07 MX MXPA03006310A patent/MXPA03006310A/es unknown
- 2002-03-07 CA CA002436911A patent/CA2436911A1/en not_active Abandoned
- 2002-03-07 ES ES02707031T patent/ES2241994T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527510A5 (enExample) | ||
| TWI250159B (en) | Imidazo pyridine derivatives which inhibit gastric acid secretion | |
| ES2614053T3 (es) | Heteroarilos de 5 miembros y su uso como antivirales | |
| JP2012505234A5 (enExample) | ||
| JP2003128673A5 (enExample) | ||
| JPWO2023099612A5 (enExample) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| WO2010042684A4 (en) | Pyrrolotriazine kinase inhibitors | |
| CA2485143A1 (en) | Carbamate-substituted pyrazolopyridines | |
| RU2009125578A (ru) | Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний | |
| JP2004523585A5 (enExample) | ||
| JP2008509187A5 (enExample) | ||
| JP2016504392A (ja) | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 | |
| JP2008530099A5 (enExample) | ||
| CA2506242A1 (en) | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain | |
| JP2013540712A5 (enExample) | ||
| JP2007517006A5 (enExample) | ||
| RU2007121219A (ru) | Диазациклоалканы как агонисты окситоцина | |
| RU2009144538A (ru) | Новые циклические пептидные соединения | |
| JP2007517007A5 (enExample) | ||
| JP2004528320A5 (enExample) | ||
| CN101778628B (zh) | 治疗焦虑的方法 | |
| JP6483272B2 (ja) | 白色脂肪組織の褐色化を誘導するための化合物および方法 | |
| ES2657942T3 (es) | Compuestos de metanotiona que tienen actividad antiviral | |
| AP2002002462A0 (en) | Pharmaceutically active compounds. |